Published in Ann Oncol on August 01, 1998
Primary pericardial sarcoma: a case report and a brief review. Cardiol Res Pract (2011) 0.87
Utility values for advanced soft tissue sarcoma health States from the general public in the United kingdom. Sarcoma (2013) 0.86
Cardiovascular toxicities from systemic breast cancer therapy. Front Oncol (2014) 0.81
High-dose ifosfamide for soft tissue sarcomas: set the scene, or senescence? Ann Oncol (1998) 0.79
Neoadjuvant and adjuvant chemotherapy with modified mesna, adriamycin, ifosfamide, and dacarbazine (MAID) regimen for adult high-grade non-small round cell soft tissue sarcomas. Int J Clin Oncol (2011) 0.79
Management of advanced adult soft tissue sarcoma. Sarcoma (2003) 0.79
Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. Br J Cancer (2006) 0.77
Acute respiratory distress syndrome caused by pulmonary and extrapulmonary disease. Different syndromes? Am J Respir Crit Care Med (1998) 3.53
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol (2013) 2.53
Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol (1994) 2.38
Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer (1987) 2.18
Methods for intense aeration, growth, storage, and replication of bacterial strains in microtiter plates. Appl Environ Microbiol (2000) 2.10
Genetic predisposition to human lung cancer. Br J Cancer (1986) 1.94
Patients' estimation of overall treatment burden: why not ask the obvious? J Clin Oncol (2002) 1.93
The effects of body mass on lung volumes, respiratory mechanics, and gas exchange during general anesthesia. Anesth Analg (1998) 1.85
Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer (1994) 1.79
Relative predispositional effects of HLA class II DRB1-DQB1 haplotypes and genotypes on type 1 diabetes: a meta-analysis. Tissue Antigens (2007) 1.77
The cell cycle control gene ZAC/PLAGL1 is imprinted--a strong candidate gene for transient neonatal diabetes. Hum Mol Genet (2000) 1.76
North-South twinning in paediatric haemato-oncology: the La Mascota programme, Nicaragua. Lancet (1998) 1.75
Molecular diagnosis of a familial nonhemolytic hyperbilirubinemia (Gilbert's syndrome) in healthy subjects. Hepatology (2000) 1.74
Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol (2000) 1.72
Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer (2006) 1.70
Informed consent for phase I studies: evaluation of quantity and quality of information provided to patients. Ann Oncol (1995) 1.69
The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer (2003) 1.63
HLA-DR-DQ haplotypes and genotypes in Finnish patients with rheumatoid arthritis. Ann Rheum Dis (2004) 1.61
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.60
Treatment of childhood Hodgkin's disease with COPP or COPP-ABV (hybrid) without radiotherapy in Nicaragua. Ann Oncol (1997) 1.58
Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol (1996) 1.58
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.57
Sigh in acute respiratory distress syndrome. Am J Respir Crit Care Med (1999) 1.53
Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic Biol Med (1999) 1.51
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.48
Architecture and polymorphism of fibrillar supramolecular assemblies produced by in vitro aggregation of human calcitonin. J Struct Biol (1995) 1.47
Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer (2006) 1.46
Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer (1986) 1.45
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.43
2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma. Ann Oncol (1996) 1.43
Natural killer activity of lymphoid cells isolated from human ascitic ovarian tumors. Int J Cancer (1980) 1.43
Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin. Ann Oncol (1999) 1.42
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer (2006) 1.41
Prospective randomized study of endovenous radiofrequency obliteration (closure procedure) versus ligation and stripping in a selected patient population (EVOLVeS Study). J Vasc Surg (2003) 1.41
Reprinted article "Prospective randomised study of endovenous radiofrequency obliteration (closure) versus ligation and vein stripping (EVOLVeS): two-year follow-up". Eur J Vasc Endovasc Surg (2011) 1.41
Lung structure and function in different stages of severe adult respiratory distress syndrome. JAMA (1994) 1.41
Preserved merosin M-chain (or laminin-alpha 2) expression in skeletal muscle distinguishes Walker-Warburg syndrome from Fukuyama muscular dystrophy and merosin-deficient congenital muscular dystrophy. Neuropediatrics (1995) 1.41
Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol Oncol (1996) 1.39
Carotid artery revascularisation following neck irradiation: immediate and long-term results. Eur J Vasc Endovasc Surg (2011) 1.38
Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer (1996) 1.38
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol (2001) 1.38
Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.37
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol (1998) 1.35
Preclinical development of a vaccine 'against smoking'. Onkologie (2002) 1.33
Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res (1989) 1.31
Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol (1994) 1.29
Analysis of the reconstitution of oligomeric enzymes by cross-linking with glutaraldehyde: kinetics of reassociation of lactic dehydrogenase. Biochemistry (1981) 1.28
Identifying the types of missingness in quality of life data from clinical trials. Stat Med (1998) 1.28
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology (2003) 1.28
Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer. Cancer (1987) 1.26
Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res (2000) 1.24
The Perceived Adjustment to Chronic Illness Scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials. Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG). Support Care Cancer (1993) 1.23
Breast cancer: pretreatment drug resistance parameters (GSH-system, ATase, P-glycoprotein) in tumor tissue and their correlation with clinical and prognostic characteristics. Ann Oncol (1997) 1.22
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 1.21
Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. Gynecol Oncol (1997) 1.19
Isolation of an anaerobic bacterium which reductively dechlorinates tetrachloroethene and trichloroethene. Biodegradation (1997) 1.19
Trauma care in Italy: evidence of in-hospital preventable deaths. J Trauma (1994) 1.16
Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet (1994) 1.15
Respiratory system mechanics in sedated, paralyzed, morbidly obese patients. J Appl Physiol (1985) (1997) 1.15
First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol (1996) 1.15
Brain metastases from endometrial carcinoma. Gynecol Oncol (1996) 1.15
The reconstitution of denatured phosphoglycerate mutase. J Biol Chem (1983) 1.10
Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol (2008) 1.10
Dose-proportionality of oral thioctic acid--coincidence of assessments via pooled plasma and individual data. Eur J Pharm Sci (1999) 1.09
A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol (1994) 1.09
Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis (2005) 1.09
Rat hepatic sinusoidal endothelial cells in monolayer culture. Biochemical and ultrastructural characteristics. J Hepatol (1988) 1.07
Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.06
Prospective randomised study of endovenous radiofrequency obliteration (closure) versus ligation and vein stripping (EVOLVeS): two-year follow-up. Eur J Vasc Endovasc Surg (2005) 1.06
Relationship between the incidence of type 1 diabetes and maternal enterovirus antibodies: time trends and geographical variation. Diabetologia (2005) 1.06
Natural cytotoxicity on tumour cells of human macrophages obtained from diverse anatomical sites. Clin Exp Immunol (1980) 1.06
Socio-demographic and medical characteristics of advanced cancer patients using conventional or complementary medicine. Onkologie (2002) 1.05
Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer (2008) 1.05
Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers. Hum Reprod (1998) 1.04
Neoadjuvant chemotherapy with cisplatin, ifosfamide and paclitaxel for locally advanced squamous-cell cervical cancer. Ann Oncol (1998) 1.04
Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann Oncol (2004) 1.03
The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases. Eur J Gynaecol Oncol (2002) 1.03
The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Curr Drug Targets (2010) 1.03
Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol (1999) 1.02
Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy. Int J Gynecol Cancer (2002) 1.01
Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br J Cancer (1999) 1.01
Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. Eur J Cancer (2008) 1.00
Evidence for active intermediates during the reconstitution of yeast phosphoglycerate mutase. Biochemistry (1985) 1.00
Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. Br J Cancer (2013) 0.99
Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol (1996) 0.99
Defining the role of extended saphenofemoral junction ligation: a prospective comparative study. J Vasc Surg (2000) 0.98
Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma? Ann Oncol (2000) 0.98
Influence of food intake on the bioavailability of thioctic acid enantiomers. Eur J Clin Pharmacol (1996) 0.98
Ultrastructural localization of proteins involved in sea urchin biomineralization. J Histochem Cytochem (1999) 0.98
Bridge to lung transplantation by venovenous extracorporeal membrane oxygenation: a lesson learned on the first four cases. Transplant Proc (2010) 0.98
Pharmacokinetics of VP16-213 given by different administration methods. Cancer Chemother Pharmacol (1982) 0.98
Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res (1986) 0.98
Adenocarcinoma of the rete testis. J Urol (2000) 0.98